Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of "Buy" from Analysts

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) have been given a consensus recommendation of "Buy" by the seven research firms that are currently covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $11.00.

A number of research firms have recently commented on AQST. JMP Securities reaffirmed a "market outperform" rating and set a $9.00 price objective on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. Cantor Fitzgerald initiated coverage on Aquestive Therapeutics in a research report on Tuesday, December 17th. They set an "overweight" rating and a $17.00 price target on the stock. Leerink Partners raised their price target on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an "outperform" rating in a report on Friday, October 25th. Finally, HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research note on Friday, December 20th.

Aquestive Therapeutics Trading Up 0.3 %

AQST stock traded up $0.01 during trading on Wednesday, reaching $3.10. 1,162,436 shares of the stock were exchanged, compared to its average volume of 1,382,542. Aquestive Therapeutics has a twelve month low of $2.24 and a twelve month high of $6.23. The company has a market capitalization of $282.66 million, a P/E ratio of -6.89 and a beta of 2.71. The stock has a 50 day simple moving average of $3.97 and a 200-day simple moving average of $4.16.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01). The business had revenue of $13.54 million during the quarter, compared to the consensus estimate of $12.69 million. During the same period in the prior year, the company earned ($0.03) EPS. Equities analysts predict that Aquestive Therapeutics will post -0.46 EPS for the current year.

Institutional Investors Weigh In On Aquestive Therapeutics

Several large investors have recently modified their holdings of AQST. Victory Capital Management Inc. bought a new stake in Aquestive Therapeutics during the 2nd quarter worth approximately $27,000. nVerses Capital LLC acquired a new position in shares of Aquestive Therapeutics in the third quarter valued at approximately $28,000. The Manufacturers Life Insurance Company bought a new stake in shares of Aquestive Therapeutics during the second quarter worth $76,000. Harvey Capital Management Inc. acquired a new stake in shares of Aquestive Therapeutics during the third quarter worth $88,000. Finally, Intech Investment Management LLC bought a new stake in Aquestive Therapeutics in the 3rd quarter valued at $90,000. 32.45% of the stock is currently owned by institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.